Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUNASDAQ:MDXHNASDAQ:SERANASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsMDXHMDxHealth$1.78$1.59$1.35▼$3.50$84.17M1.3284,180 shs126,547 shsSERASera Prognostics$2.25-4.3%$3.36$2.10▼$9.91$84.74M0.99131,863 shs222,166 shsXGNExagen$5.82+3.4%$4.70$1.67▼$7.20$104.77M1.5108,754 shs107,507 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%MDXHMDxHealth0.00%+4.71%+14.10%-3.26%-38.19%SERASera Prognostics-4.26%-6.56%-32.63%-47.31%-73.05%XGNExagen+3.37%-14.79%+26.52%+36.30%+230.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUAkuminN/AN/AN/AN/AN/AN/AN/AN/AMDXHMDxHealth2.5289 of 5 stars3.53.00.00.02.90.01.3SERASera Prognostics0.9925 of 5 stars0.04.00.00.02.52.50.0XGNExagen4.4078 of 5 stars3.53.00.04.52.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/AMDXHMDxHealth 3.00Buy$6.50265.17% UpsideSERASera Prognostics 0.00N/AN/AN/AXGNExagen 3.00Buy$8.0037.46% UpsideCurrent Analyst Ratings BreakdownLatest AKU, XGN, SERA, and MDXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/12/2025XGNExagenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00MDXHMDxHealth$90.05M0.93N/AN/A$4.62 per share0.39SERASera Prognostics$77K1,100.57N/AN/A$2.21 per share1.02XGNExagen$56.72M1.85N/AN/A$1.33 per share4.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/AMDXHMDxHealth-$43.10M-$1.27N/AN/AN/A-49.52%-1,077.84%-28.82%N/ASERASera Prognostics-$36.24M-$0.94N/AN/AN/AN/A-51.73%-36.94%N/AXGNExagen-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%N/ALatest AKU, XGN, SERA, and MDXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MDXHMDxHealth-$0.13-$0.19-$0.06-$0.19$22.62 millionN/A5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 million2/26/2025Q4 2024MDXHMDxHealth-$0.21-$0.14+$0.07-$0.14$22.67 million$24.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/AMDXHMDxHealthN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99MDXHMDxHealth3.141.541.45SERASera PrognosticsN/A2.112.11XGNExagen1.544.054.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%MDXHMDxHealthN/ASERASera Prognostics54.64%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%MDXHMDxHealth1.70%SERASera Prognostics13.50%XGNExagen26.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableMDXHMDxHealth30047.29 million46.48 millionNot OptionableSERASera Prognostics12037.66 million28.44 millionOptionableXGNExagen22018.00 million13.03 millionOptionableAKU, XGN, SERA, and MDXH HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Takes Position in Exagen Inc. (NASDAQ:XGN)May 12 at 5:26 AM | marketbeat.comExagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call TranscriptMay 11, 2025 | insidermonkey.comWilliam Blair Has Pessimistic Outlook of Exagen Q2 EarningsMay 10, 2025 | marketbeat.comWilliam Blair Issues Negative Outlook for Exagen EarningsMay 10, 2025 | americanbankingnews.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional SharesMay 9, 2025 | finance.yahoo.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesMay 9, 2025 | globenewswire.comWilliam Blair Forecasts Exagen's Q1 Earnings (NASDAQ:XGN)May 9, 2025 | marketbeat.comEquities Analysts Set Expectations for Exagen Q1 EarningsMay 9, 2025 | americanbankingnews.comExagen Inc. Prices Public Offering of Common StockMay 8, 2025 | globenewswire.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7, 2025 | globenewswire.comExagen (NASDAQ:XGN) Issues Quarterly Earnings ResultsMay 7, 2025 | marketbeat.comExagen (XGN) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6, 2025 | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 6, 2025 | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5, 2025 | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comExagen Inc. (XGN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comExagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeMay 5, 2025 | globenewswire.comExagen Inc (XGN) Q1 2025 Earnings Report Preview: What To ExpectMay 3, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKU, XGN, SERA, and MDXH Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.MDxHealth NASDAQ:MDXH$1.78 0.00 (0.00%) As of 05/14/2025 03:59 PM EasternMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Sera Prognostics NASDAQ:SERA$2.25 -0.10 (-4.26%) As of 05/14/2025 04:00 PM EasternSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Exagen NASDAQ:XGN$5.82 +0.19 (+3.37%) As of 05/14/2025 04:00 PM EasternExagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
